Restoration of vision by combined experimental antithymocyte therapy, and orbital radiation with high-dose steroids for severe, acute, steroid-refractory, congestive thyroid orbitopathy
Springer Science and Business Media LLC - Trang 1-9 - 2023
Tóm tắt
We report diagnostic and therapeutic dilemmas in the difficult case of compressive optic neuropathy with severe visual acuity and visual field loss with subsequent visual recovery in both eyes, in a patient with Graves’ orbitopathy (GO) by a combination of experimental antithymocyte therapy, orbital radiotherapy with high-dose steroids. A 72-year-old man presented with severe vision loss in both eyes. The visual symptoms had appeared over a year before the GO diagnosis. He was initially misdiagnosed with neuroborreliosis and optic neuritis based on brain and orbital magnetic resonance imaging. There was no exophthalmos. The ophthalmological examination included visual acuity, visual field, tonometry in primary and upgaze eye position, optical coherence tomography (OCT), pattern electroretinogram (PERG), pattern, and flash visual evoked potentials (PVEP and FVEP). The patient received experimental therapy with ATG, followed by high-dose of intravenous steroids and orbital radiotherapy. Delayed VEP peaks became shorter after treatment. After systemic and local therapy lowering of intraocular pressure was achieved. Abnormal PERG has been found three months before ganglion cells atrophy was detected in OCT. Visual acuity and visual field improvement occurred in both eyes after therapy, despite partial left optic nerve atrophy. The patient regained full decimal visual acuity (1.0 right from as poor as 0.3 to 1.0 in the right eye and from hand movements to 0.9 in the left. Severe visual field loss with advanced absolute scotomata has improved to slight relative scotomata. The duration of follow-up time after the treatment was 4 months. Intensive treatment of steroid-resistant Graves’ orbitopathy (GO) may prevent total optic nerve atrophy. Despite severely advanced optic neuropathy, this report emphasizes the necessity of therapy even with nearly complete visual function loss hence there is always a possibility to regain full visual acuity and visual field. Patients with tense orbital septum may not present with significant exophthalmos, thus delaying the correct diagnosis of orbitopathy. A supporting sign of GO was the difference in intraocular pressure in the primary and upgaze eye positions. Electrophysiological examinations are helpful in the diagnosis and monitoring of GO therapy. To our knowledge, this is the first report of this kind presenting visual function restoration and structural recovery in a patient with advanced optic neuropathy in GO.
Tài liệu tham khảo
Bartalena L, Kahaly GJ, Baldeschi L et al (2021) EUGOGO †.The 2021 European group on graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol 185(4):G43–G67. https://doi.org/10.1530/EJE-21-0479
Zand MS, Vo T, Huggins J et al (2005) Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 79:1507–1515. https://doi.org/10.1097/01.tp.0000164159.20075.16
Gurkan S, Luan Y, Dhillon N et al (2010) Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 10(9):2132–2141. https://doi.org/10.1111/j.1600-6143.2010.03210.x
Świerkot M, Kulawik G, Sarnat-Kucharczyk M et al (2020) Long-term remission of steroid-resistant Graves’ orbitopathy after administration of anti-thymocyte globulin. Endokrynol Pol 71(2):198–199. https://doi.org/10.5603/EP.a2019.0067
Sarnat-Kucharczyk M, Świerkot M, Handzlik G et al (2022) Antithymocyte globulin as second-line therapy in graves orbitopathy-preliminary results from a prospective single-center study. Front Endocrinol 13:871009. https://doi.org/10.3389/fendo.2022.871009
Odom JV, Bach M, Brigell M, Holder GE, McCulloch DLL, Mizota A et al (2016) International society for clinical electrophysiology of vision: ISCEV standard for clinical visual evoked potentials–(2016 update). Doc Ophthalmol 133:1–9. https://doi.org/10.1007/s10633-016-9553-y
Bach M, Brigell MG, Hawlina M et al (2013) ISCEV standard for clinical pattern electroretinography (PERG): 2012 update. Doc Ophthalmol 126:1–7. https://doi.org/10.1007/s10633-012-9353-y
Salleh NA, Seng WH, Isa HD (2016) Optic neuropathy in thyroid eye disease: a case series. Korean J Fam Med 37(3):197–201. https://doi.org/10.4082/kjfm.2016.37.3.197
Kauh CY, Gupta S, Douglas RS et al (2015) Compressive optic neuropathy and repeat orbital decompression: a case series. Ophthalmic Plast Reconstr Surg 31(5):385–390. https://doi.org/10.1097/IOP.0000000000000356
Dolman PJ (2018) Grading severity and activity in thyroid eye disease. Ophthalmic Plast Reconstr Surg 34(4S Suppl 1):S34–S40. https://doi.org/10.1097/IOP.0000000000001150
Miskiewicz P, Rutkowska B, Jabłońska A et al (2016) Complete recovery of visual acuity as the main goal of treatment in patients with dysthyroid optic neuropathy. Endokrynol Pol 67(2):166–173. https://doi.org/10.5603/EP.a2016.0018
Cyranska-Chyrek E, Olejarz M, Szczepanek-Parulska E et al (2019) Severe unilateral orbitopathy in a patient with Hashimoto’s thyroiditis–a case report. BMC Ophthalmol 19(1):9. https://doi.org/10.1186/s12886-018-1018-5
Iao TWU, Rong SS, Ling AN et al (2017) Electrophysiological studies in thyroid associated orbitopathy: a systematic review. Sci Rep 7(1):12108. https://doi.org/10.1038/s41598-017-11998-0
Eslami F, Borzouei S, Khanlarzadeh E et al (2019) Prevalence of increased intraocular pressure in patients with Graves’ ophthalmopathy and association with ophthalmic signs and symptoms in the north-west of Iran. Clin Ophthalmol 13:1353–1359. https://doi.org/10.2147/OPTH.S205112
Ambrosio G, Ferrara G, Vitale R et al (2003) Visual evoked potentials in patients with Graves’ ophthalmopathy complicated by ocular hypertension and suspect glaucoma or dysthyroid optic neuropathy. Doc Ophthalmol 106(2):99–104. https://doi.org/10.1023/a:1022561530782